Pure Global

Delivery Catheter System - India CDSCO Medical Device Registration

Delivery Catheter System is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/MD/2019/000213_6c5a96fb2f9b6013a7d68b42c221abbd_6b233dafd86d30a15c96b60fdc64a681. This device is marketed under the brand name Enveo Pro. The license holder is India Medtronic Private Limited ,Shed No. 3, Block No. 1, Survey No. 389, 400/2A & 2C, Pudur Main Road, Kuthambakkam - 600124, Poonamallee Taluk, Tiruvallur District ,Tiruvallur Tamil Nadu ,600124 ,India, and it is classified as Device Class Class C. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class C
Delivery Catheter System
UID: IMP/MD/2019/000213_6c5a96fb2f9b6013a7d68b42c221abbd_6b233dafd86d30a15c96b60fdc64a681

Brand Name

Enveo Pro

Device Class

Class C

Approving Authority

CDSCO

Product Information

The CoreValve Evolut R and Pro system is indicated for patients presenting with severe native aortic valve stenosis.For patients presenting with severe native bicuspid aortic valve stenosis, the CoreValve Evolut R and Pro system is indicated for patients who are at intermediate or greater risk for surgical aortic valve replacement (Enveo Pro) where intermediate risk isdefined as Society of Thoracic Surgeons operative risk score greater than or equal to4% or documented heart team agreement of risk for AVR due to frailty or comorbidities.For patients presenting at low risk for AVR (Enveo Pro), the system is indicated for patients greater than or equal to70 years of age with an LVEF >30%.The CoreValve Evolut R and Pro system is also indicated for patients with a stenosed, insufficient, or combined surgical bioprosthetic valve failure necessitating valve replacement who are at high or greater risk for surgical aortic valve replacement (Enveo Pro) where high risk is defined as Society of Thoracic Surgeons operative risk score greater than or equal to8% or documented heart team agreement of risk for AVR due to frailty or comorbidities.

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing